11th Annual Proteins & Antibodies Congress, 16-17 April 2018, London, UK

  • Check with publisher
  • Published date: August 24, 2017
    • London, United Kingdom

Oxford Global Conferences are proud to present our 11th Annual Proteins & Antibodies Congress, 16-17 April 2018, London, UK with our co-located 5th Annual Peptides Congress and 5th Annual Biosimilars & Biobetters Congress. Across the two days, over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.

Over 50 case studies, presentations and panel discussions focused on the key issues in protein and antibody engineering & development, protein & antibody biotherapeutics as well as biotherapeutics manufacturing and chemistry.

Including 5 interactive streams:
• Protein Engineering, Design & Selection
• Biotherapeutics: Manufacturing, Chemistry, Analytics and Control
• Antibody Engineering, Design & Development
• Cloning, Expressions, Purification & Analytics
• Protein & Antibody Biotherapeutics

Download Agenda: http://bit.ly/2iqjUH3

Free Live Webinars

Protein & Antibody Biotherapeutics – Manufacturing & Developability Assessment
Hosted by David Gervais, Head of Product Development, Porton Biopharma and Thorsten Lorenz, Group Head Developability Assessment 1, Novartis
Register for Free Today: http://bit.ly/2g4nJRl

Antibody Biotherapeutics: Current Technologies And Recent Therapeutic Success
Hosted by David Mantus, Chief Development Officer, Arsanis and Pallavi Tawde, Single B Cell Cloning Platform Leader, Bristol-Myers Squibb
Register for Free Today: http://bit.ly/2wnmDqw

For further information regarding prices and possible discounts, please contact Danielle Dalby on d.dalby@oxfordglobal.co.uk or call +44 (0)1865 248 455.

Result 0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Magic™ Humanized PD-1 Immune Checkpoint Knock-In Mice

    Magic™ Humanized PD-1 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    Management of cancer is a big problem, not only because the difficulties in developing new drugs but also because tumor cells usually acquire resistance to anti-cancer drugs to avoid immune destruction (immune escape). One of the most important mecha...

  • Magic™ Humanized LAG3 Immune Checkpoint Knock-In Mice

    Magic™ Humanized LAG3 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    Recent achievements in cancer immunotherapy especially immune checkpoint modulators are reshaping the way of conventional cancer treatment. Nowadays, the rapid development of immune checkpoint targeting drugs has become one of the hotspots that are a...

  • Magic™ Humanized OX40 Immune Checkpoint Knock-In Mice

    Magic™ Humanized OX40 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    Administration of anti-OX40 increases proliferation of peripheral blood CD4+ and CD8+ T cells, increases responses to recall and naïve reporter Ags, and increases endogenous tumor-specific immune responses. Several agonistic anti-OX40 antibodies are ...